SAS Output

21-AUG-2019 6:10

GU ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1500-pRCC,Adv, Sunitinib vs MET inhib 1 Y 1 Sunitinib 148 39 14 7 5 2 1 07/25/2016 215 88
        2 Cabozantinib   37 12 8 4 0 0      
        3 Crizotinib   28 0 0 0 0 0      
        4 Savolitinib   30 4 0 0 0 0      
            134 30 15 9 2 1      
 
  S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 969 166 119 86 45 16 4 02/24/2017 188 89
        2 Tokyo-172 BCG   165 119 86 45 18 4      
        3 Prime + Tokyo-172 BCG   166 119 90 45 17 4      
            497 357 262 135 51 12      
 
  S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 1273 87 87 52 25 12 3 09/24/2018 266 114
            87 87 52 25 12 3      
 
    2 Y 1 Standard Systemic Therapy Only 1273 23 23 18 7 4 0 09/24/2018    
        2 SST + Surgery/RT   25 25 19 11 6 2      
            48 48 37 18 10 2      
 
  S1806-Blad, MIBC, ChemoRT +/- Atezolizumab 1 Y 0 Initial Registration 475 9 9 9 9 6 2 06/03/2019 189 89
            9 9 9 9 6 2      
 
    2 Y 1 Chemo + RT 475 5 5 5 5 3 1 06/03/2019    
        2 Chemo + RT + Atezolizumab   3 3 3 3 2 0      
            8 8 8 8 5 1      
 
Yes A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 1 E Total Registrations   6 3 2 1 0 0 11/23/2016 61 37
            6 3 2 1 0 0      
 
  A031702-GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) 1 E Total Registrations   2 2 2 2 2 0 08/09/2019    
            2 2 2 2 2 0      
 
  EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER) 0 E Total Registrations   59 40 27 11 5 0 09/29/2017 253 126
            59 40 27 11 5 0      
 
    1 E Total Registrations   50 35 26 9 5 0 09/29/2017    
            50 35 26 9 5 0      
 
  EA8171-PROS, newly diagnosed, mpMRI for pre-op stagi 1 E Total Registrations   9 9 7 4 2 0 02/11/2019 81 34
            9 9 7 4 2 0      
 
  NRGGU002-Pros, RT + ADT After RP +/- Adj Docetaxel 1 E Total Registrations   3 2 1 0 0 0 08/24/2017 233 118
            3 2 1 0 0 0      
 
    2 E Total Registrations   3 2 1 0 0 0 08/24/2017    
            3 2 1 0 0 0      
 
  NRGGU005-PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT 1 E Total Registrations   1 1 1 0 0 0 03/19/2019 241 105
            1 1 1 0 0 0      
 
  NRGGU006-PROS, post-RP PSA, SRT +/- ADT w/Apalutamide 1 E Total Registrations   2 2 2 0 0 0 03/22/2019 54 21
            2 2 2 0 0 0      
 
    2 E Total Registrations   2 2 2 0 0 0 03/22/2019    
            2 2 2 0 0 0      
 
No A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 0 E Total Registrations   49 40 21 11 4 1 05/03/2018 222 130
            49 40 21 11 4 1      
 
    1 E Total Registrations   46 39 22 10 6 2 05/03/2018    
            46 39 22 10 6 2      
 
  A031701-Bladder, ddGC for MIBC with DDR Tumor Alt 1 E Total Registrations   1 1 0 0 0 0 12/17/2018 100 43
            1 1 0 0 0 0      
 
    2 E Total Registrations   1 1 1 0 0 0 12/17/2018    
            1 1 1 0 0 0      
 
  EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT 1 E Total Registrations   2 2 2 1 1 1 04/25/2019    
            2 2 2 1 1 1      
 
  EA8153-Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 1 E Total Registrations   9 7 5 3 2 0 08/08/2018 234 94
            9 7 5 3 2 0